

Regional TB and Mycobacterial Infections
Journal Club

SimpliciTB Trial

Friday
2nd August
12pm AEST

SimpliciTB was an open-label trial that evaluated the efficacy, safety and tolerability of bedaquiline (B), pretomanid (Pa), moxifloxacin (M) and pyrazinamide (Z) (BPamZ) for patients with drug-sensitive (DS) and drug-resistant pulmonary tuberculosis (MDR and mono-resistance to isoniazid and rifampicin). The findings has important implications for the potential efficacy of the regimen but is sobered by the safety signal seen. Dr Catherine Berry and Dr Holly Jordan from the Hunter New England LHD will present the paper, following by a discussion of what we can take away from this trial.



Dr Catherine Berry

Dr Catherine Berry is an Infectious Diseases consultant with the Hunter New England Local Health District and a conjoint lecturer at the University of Newcastle. She has extensive experience in treating patients with multi-drug resistant (MDR) TB and served as the Global Principal Investigator for the TB-PRACTECAL trial. She also supports the endTB initiative.



Dr Holly Jordan

Dr Holly Jordan is a final-year Infectious Diseases and General Medicine advanced trainee with the Hunter New England Local Health District. She has completed her Master of Tropical Medicine and Public Health and has a particular interest in neglected tropical diseases, including mycobacterial infections, and their complex interactions with social determinants of health.

TB Regional Journal Club



2nd August - 12pm AEST

<https://url.au.m.mimecastprotect.com/s/hyEWC71R2NTEoK7kjl8aT8M?domain=burnet-edu-au.zoom.us>



Australasian Clinical Tuberculosis Network